MRVI vs. LRCX
MRVI (Maravai LifeSciences Holdings, Inc.) and LRCX (Lam Research Corporation) are both stocks. MRVI operates in Biotechnology (Healthcare), while LRCX operates in Semiconductor Equipment & Materials (Technology). Over the past 5 years, MRVI returned -31.63%/yr vs 37.09%/yr for LRCX. Their 0.21 correlation means their historical movements had little consistent relationship.
Performance
MRVI vs. LRCX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MRVI achieves a 102.15% return, which is significantly higher than LRCX's 71.50% return.
MRVI
- 1D
- -2.67%
- 1M
- 8.77%
- 6M
- 95.54%
- YTD
- 102.15%
- 1Y
- 195.95%
- 3Y*
- -15.86%
- 5Y*
- -31.63%
- 10Y*
- —
- ALL TIME*
- -24.26%
LRCX
- 1D
- -1.58%
- 1M
- -16.62%
- 6M
- 25.75%
- YTD
- 71.50%
- 1Y
- 205.74%
- 3Y*
- 61.40%
- 5Y*
- 37.09%
- 10Y*
- 43.64%
- ALL TIME*
- 23.67%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $3.65B | $3.82B | $3.92B | |
| $14.10M | $18.27M | $16.79M |
MRVI vs. LRCX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
MRVI Maravai LifeSciences Holdings, Inc. | 102.15% | -40.37% | -16.79% | -54.23% | -65.85% | 49.38% | -12.21% |
LRCX Lam Research Corporation | 71.50% | 139.16% | -6.84% | 88.63% | -40.72% | 53.66% | 8.18% |
Correlation
The correlation between MRVI and LRCX is 0.22, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.22 |
Correlation (3Y) Balances recent behavior with more history. | 0.13 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.19 |
Correlation (All Time) Calculated using the full available price history since Nov 20, 2020 | 0.21 |
Fundamentals
MRVI:
$1.81B
LRCX:
$366.44B
MRVI:
-$0.72
LRCX:
$5.75
MRVI:
4.67
LRCX:
15.93
MRVI:
4.55
LRCX:
29.63
MRVI:
$204.73M
LRCX:
$23.23B
MRVI:
$59.37M
LRCX:
$11.73B
MRVI:
-$118.27M
LRCX:
$8.70B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MRVI vs. LRCX — Risk / Return Rank
MRVI
LRCX
MRVI vs. LRCX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Maravai LifeSciences Holdings, Inc. (MRVI) and Lam Research Corporation (LRCX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MRVI | LRCX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.79 | ||
| Sortino ratioReturn per unit of downside risk | -0.01 | ||
| Omega ratioGain probability vs. loss probability | 1.40 | 1.42 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 6.15 | 5.08 | +1.07 |
| Martin ratioReturn relative to average drawdown | 15.22 | 21.44 | -6.22 |
Loading charts...
Drawdowns
MRVI vs. LRCX - Drawdown Comparison
The maximum MRVI drawdown since its inception was -97.16%, which is greater than LRCX's maximum drawdown of -87.90%. Use the drawdown chart below to compare losses from any high point for MRVI and LRCX.
Loading charts...
Drawdown Indicators
| MRVI | LRCX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.16% | -87.90% | -9.26% |
Max Drawdown (1Y)Largest decline over 1 year | -29.60% | -41.76% | +12.16% |
Max Drawdown (3Y)Largest decline over 3 years | -85.04% | -47.10% | -37.94% |
Max Drawdown (5Y)Largest decline over 5 years | -97.16% | -56.39% | -40.77% |
Max Drawdown (10Y)Largest decline over 10 years | — | -56.39% | — |
Current DrawdownCurrent decline from peak | -89.16% | -32.38% | -56.78% |
Average DrawdownAverage peak-to-trough decline | -68.32% | -28.13% | -40.19% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.93% | 9.87% | +2.06% |
Volatility
MRVI vs. LRCX - Volatility Comparison
The current volatility for Maravai LifeSciences Holdings, Inc. (MRVI) is 14.16%, while Lam Research Corporation (LRCX) has a volatility of 27.34%. This indicates that MRVI experiences smaller price fluctuations and is considered to be less risky than LRCX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MRVI | LRCX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.16% | 27.34% | -13.18% |
Volatility (6M)Calculated over the trailing 6-month period | 41.27% | 52.39% | -11.12% |
Volatility (1Y)Calculated over the trailing 1-year period | 70.65% | 63.10% | +7.55% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 74.90% | 48.97% | +25.93% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 72.96% | 46.20% | +26.76% |
Dividends
MRVI vs. LRCX - Dividend Comparison
MRVI has not paid dividends to shareholders, while LRCX's dividend yield for the trailing twelve months is around 0.35%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LRCX Lam Research Corporation | 0.35% | 0.57% | 1.19% | 0.95% | 1.53% | 0.78% | 1.04% | 1.54% | 2.79% | 1.01% | 1.28% | 1.36% |
MRVI Maravai LifeSciences Holdings, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
MRVI vs. LRCX - Financials Comparison
This section allows you to compare key financial metrics between Maravai LifeSciences Holdings, Inc. and Lam Research Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
MRVI vs. LRCX - Profitability Comparison
MRVI - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Maravai LifeSciences Holdings, Inc. reported a gross profit of 33.70M and revenue of 65.84M. Therefore, the gross margin over that period was 51.2%.
LRCX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Lam Research Corporation reported a gross profit of 3.48B and revenue of 6.72B. Therefore, the gross margin over that period was 51.8%.
MRVI - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Maravai LifeSciences Holdings, Inc. reported an operating income of 720.00K and revenue of 65.84M, resulting in an operating margin of 1.1%.
LRCX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Lam Research Corporation reported an operating income of 2.51B and revenue of 6.72B, resulting in an operating margin of 37.4%.
MRVI - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Maravai LifeSciences Holdings, Inc. reported a net income of -3.73M and revenue of 65.84M, resulting in a net margin of -5.7%.
LRCX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Lam Research Corporation reported a net income of 2.28B and revenue of 6.72B, resulting in a net margin of 33.9%.
Frequently Asked Questions
MRVI and LRCX have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LRCX has higher volatility (27.34%) compared to MRVI (14.16%). In terms of maximum drawdown, MRVI dropped -97.16% vs LRCX's -87.90%.
LRCX currently has the higher Sharpe Ratio (3.37 vs 2.58), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MRVI and LRCX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer